Piramal Pharma Intrinsic Value
Piramal Pharma intrinsic value. Piramal Pharma (PPLPHARMA) median intrinsic value is ₹121.18 from 8 valuation models (range ₹72–₹169), vs current price ₹239.65 — -49.4% downside (Trading Above Calculated Value), margin of safety -97.8%. Analyse Piramal Pharma ownership structure to track promoter, FII and institutional holdings.
PPLPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Piramal Pharma intrinsic value across 8 models vs current price ₹239.65 — upside/downside and value range per method. For current market price and key ratios, visit Piramal Pharma share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹71.89 | ₹57.51 - ₹86.27 | -70.0% | EPS: ₹0.16, Sector P/E: 22x |
| Book Value Method | asset | ₹123.03 | ₹110.73 - ₹135.33 | -48.7% | Book Value/Share: ₹61.51, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹161.02 | ₹144.92 - ₹177.12 | -32.8% | Revenue/Share: ₹80.51, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹121.18 | ₹109.06 - ₹133.30 | -49.4% | EBITDA: ₹1608.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹169.20 | ₹135.36 - ₹203.04 | -29.4% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹71.89 | ₹64.70 - ₹79.08 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹71.89 | ₹64.70 - ₹79.08 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹71.89 | ₹64.70 - ₹79.08 | -70.0% | EPS: ₹0.16, BVPS: ₹61.51 |
PPLPHARMA Intrinsic Value vs Market Price — All Valuation Models
Piramal Pharma fair value range ₹72–₹169 vs current market price ₹239.65 across 8 valuation models. Browse PPLPHARMA cash flow statement for revenue, profit, balance sheet and cash flow data.
PPLPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Piramal Pharma median intrinsic value ₹121.18, current price ₹239.65 — Trading Above Calculated Value by 49.4%, margin of safety -97.8%.
What is the intrinsic value of PPLPHARMA?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Piramal Pharma (PPLPHARMA) is ₹121.18 (median value). With the current market price of ₹239.65, this represents a -49.4% variance from our estimated fair value.
The valuation range spans from ₹71.89 to ₹169.20, indicating ₹71.89 - ₹169.20.
Is PPLPHARMA undervalued or overvalued?
Based on our multi-method analysis, Piramal Pharma (PPLPHARMA) appears to be trading above calculated value by approximately 49.4%.
PPLPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Piramal Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 0.2% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.59x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
PPLPHARMA Cash Flow Quality — Operating & Free Cash Flow
Piramal Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹1,653 Cr | ₹1,243 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹892 Cr | ₹648 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1,005 Cr | ₹797 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹484 Cr | ₹-183 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹766 Cr | ₹-103 Cr | Positive Operating Cash Flow | 6/10 |